You can buy or sell KNSA and other stocks, options, ETFs, and crypto commission-free!
Kiniksa Pharmaceuticals, Ltd. Class A Common Stock, also called Kiniksa Pharmaceuticals, is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Read More Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
52 Week High
52 Week Low
— per share
Expected Aug 12, Pre-Market